Infantile Malignant Osteopetrosis clinical trials at UC Health

• A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis

  open to eligible people ages 1 month and up

  The primary objective of this Phase 1 study is to evaluate the therapeutic safety and feasibility of the investigational product (IP), RP-L401.

  at UCLA

Last updated: March 12, 2021